Name: Baylor College of Medicine - BioCentury Company Profiles - BCIQ
Creator: Biocentury

signInButton

SIGN IN

Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Please note, you are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry. Request a trial to unlock the full value of BCIQ.

REQUEST A FREE TRIAL

AcquiredOrMerged

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.

If you believe a company has been archived in error, please contact us at 

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.\nIf you believe a company has been archived in error, please contact us at \nsupport@biocentury.com\n.

Cat-H(AcquiredorMerged)

Historical deals and financings can be found by searching the organization's name in the BCIQ <DEALS> and <FINANCING> Modules.

Default (Company Type Blank)

CategoryHDefault (Company Type Blank)

NonBioPharma

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.

Cat-H(NonBioPharma)

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.\n

Baylor College of Medicine

Science Spotlight: TGFβ drives long COVID inflammation via EBV

Inhibiting histone serotonylation for ependymoma

STK33 inhibitor for reversible male contraception

John Milad named CEO of CRISPR play ERS Genomics

Small-molecule TopBP1 inhibitor for breast and ovarian cancers

Mini Cas protein iterations; plus Moderna’s Lassa virus vaccine and more

Targeting IRE1 in KRASi-resistant tumors; plus AZ’s Cas9 variant and more

Single-cell T cell atlas identifies new subsets; plus CoRegen’s cell therapy and more

Ubiquitin-regulation for tauopathies; plus Regeneron’s IL2RG mAb for T cell-driven disease and more

Cajal: integrating anatomy and genetics to discover CNS targets